Another new entry point for the treatment of NAFLD is the NR4A1 (nuclear receptor subfamily four group A member 1)/DNA-PKcs (DNA-dependent protein kinase catalytic subunit)/p53 pathway. Here, TP53 is linked to metabolic dysfunction-associated steatotic liver disease.